Literature DB >> 3978241

The effect of low-dose estroprogestinic preparations on prothrombin complex factors: no significant increase after an 8-month trial.

A Girolami, M Procidano, M Vicariotto, G Cappellato, T Vicari.   

Abstract

The behavior of the prothrombin complex factors in 16 healthy women during low-dose estroprogestinic treatment (laevonorgestrel 0.15 mg and ethynilestradiol 0.30 mg) at basal conditions and during 8 months of therapy has been investigated. We found a statistically significant decrease of the PTT (Partial Thromboplastin Time). The prothrombin time, on the other hand, became slightly decreased, but not to a statistically significant extent. Among the prothrombin time derived tests for evaluating the prothrombin complex only the PP test (Prothrombin Proconvertin test) was significantly shortened. Of the coagulation factors (factors II, VII and X) only a modest, but not statistically significant, increase in Factor VII and Factor X was noted. We conclude that, during the 8 month observation period, prothrombin complex factors are not altered substantially.

Entities:  

Keywords:  Biology; Cardiovascular Effects; Cerebrovascular Effects; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Methods--side effects; Diseases; Embolism; Endocrine System; Ethinyl Estradiol; Family Planning; Hormones; Levonorgestrel; Oral Contraceptives--side effects; Physiology; Reproductive Control Agents; Thromboembolism; Vascular Diseases

Mesh:

Substances:

Year:  1985        PMID: 3978241     DOI: 10.1007/bf00320070

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  24 in total

Review 1.  Oral contraceptives, blood clotting and thrombosis.

Authors:  L Poller
Journal:  Br Med Bull       Date:  1978-05       Impact factor: 4.291

2.  Intimal vascular lesions associated with female reproductive steroids.

Authors:  N S Irey; H J Norris
Journal:  Arch Pathol       Date:  1973-10

3.  [Contraceptive agents and thrombosis].

Authors:  G A Marcel
Journal:  Pathol Biol (Paris)       Date:  1976-11

4.  The coagulation mechanism in oral contraception.

Authors:  C J Amris; J Starup
Journal:  Acta Obstet Gynecol Scand       Date:  1967       Impact factor: 3.636

5.  Coagulation abnormalities in women taking oral contraceptives.

Authors:  A C Carvalho; R A Vaillancourt; R B Cabral; R S Lees; R W Colman
Journal:  JAMA       Date:  1977-02-28       Impact factor: 56.272

6.  Low-dose oral contraceptive usage and coagulation.

Authors:  M Notelovitz; C S Kitchens; L Coone; L McKenzie; R Carter
Journal:  Am J Obstet Gynecol       Date:  1981-09-01       Impact factor: 8.661

7.  Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs.

Authors:  W H Inman; M P Vessey; B Westerholm; A Engelund
Journal:  Br Med J       Date:  1970-04-25

8.  Estrogen-containing oral contraceptive agents. A basis for their thrombogenicity.

Authors:  S Wessler; S N Gitel; L S Wan; B S Pasternack
Journal:  JAMA       Date:  1976-11-08       Impact factor: 56.272

9.  Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report.

Authors:  M P Vessey; R Doll
Journal:  Br Med J       Date:  1969-06-14

Review 10.  Oral contraceptives and blood coagulation: a critical review.

Authors:  E F Mammen
Journal:  Am J Obstet Gynecol       Date:  1982-03-15       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.